Skip to main content
. 2020 Feb 6;2020:9416803. doi: 10.1155/2020/9416803

Table 1.

Participant characteristics in evaluation and validation cohorts.

Variables Evaluation cohort (n = 324) Validation cohort (n = 136) P-value
Age (years) 62.60 ± 12.00 63.73 ± 11.70 0.3537
Male, n (%) 250 (77.16%) 103 (75.74%) 0.7425
Killip's classification > I, n (%) 92 (28.40%) 20 (14.71%) 0.0018
Diabetes mellitus, n (%) 99 (30.56%) 49 (36.03%) 0.2523
Hypertension, n (%) 195 (60.19%) 69 (50.74%) 0.0617
Myocardial infarction history, n (%) 37 (11.42%) 18 (13.24%) 0.5834
Anterior wall myocardial infarction, n (%) 160 (49.38%) 69 (50.74%) 0.7903
Apelin-12 (ng/mL) 0.82 ± 0.33 0.84 ± 0.35 0.5605
Apelin-12 change rate (%) 13.74 ± 8.98 12.94 ± 8.63 0.3783
SBP(mmHg) 131.34 ± 27.20 133.13 ± 27.10 0.5194
Albumin (g/L) 37.95 ± 3.92 37.87 ± 3.64 0.8385
Haemoglobin (g/L) 143.46 ± 17.39 144.65 ± 16.79 0.499
Total cholesterol (mmol/L) 5.67 ± 1.11 5.65 ± 1.06 0.8583
Triglyceride (mmol/L) 1.09 ± 0.85 1.16 ± 0.82 0.4159
High-density lipoprotein-C (mmol/L) 1.19 ± 0.27 1.24 ± 0.26 0.0676
Low-density lipoprotein-C (mmol/L) 3.06 ± 0.71 3.00 ± 0.76 0.4184
Fasting blood glucose (mmol/L) 7.63 ± 2.52 7.76 ± 2.57 0.6159
White blood cells × 109/L 9.95 ± 3.72 10.40 ± 3.44 0.2269
Heart rate 77.54 ± 16.97 75.42 ± 17.56 0.2268
Neutrophil (%) 75.2 ± 11.71 76.89 ± 11.03 0.1515
Creatinine (mmol/L) 75.40 ± 25.20 72.91 ± 15.58 0.2855
Uric acid (mmol/L) 339.19 ± 75.20 332.5 ± 70.63 0.376
Platelet × 109/L 232.59 ± 56.05 231.14 ± 57.02 0.8012
Blood urea nitrogen (mmol/L) 6.66 ± 2.05 6.89 ± 2.12 0.2776
Peak creatine kinase MB (U/L) 126.83 ± 91.26 130.85 ± 85.75 0.661
Peak cTnI (ng/ML) 16.66 ± 12.87 16.47 ± 12.86 0.8852
Pathological Q wave, n (%) 154 (47.53%) 67 (49.26%) 0.735
GENSINI score 72.92 ± 32.17 70.18 ± 32.18 0.405
Left atrial diameter (mm) 37.53 ± 5.59 37.17 ± 5.90 0.5356
Left ventricular diastolic diameter (mm) 50.36 ± 6.24 50.51 ± 6.36 0.8151